Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The first phase 3 trial of amyloid-β-targeting monoclonal antibodies in dominantly inherited Alzheimer’s disease failed to slow cognitive decline in patients. Could it still help to inform future study design and drug development in this setting?
The first clinical study of an oral small-molecule GLP-1 receptor agonist suggests effective glycemic control and weight loss in patients with type 2 diabetes.
A prospective cohort analysis finds a link between the ChAdOx1 vaccine and an autoimmune disorder known as immune thrombocytopenia—but questions remain and causality is yet to be established.
New advances in machine learning could facilitate and reduce disparities in the prenatal diagnosis of congenital health disease, the most common and lethal birth defect.
A multi-arm clinical trial reports results of testing a strategy for the treatment of bladder cancer that uses standard immunotherapy plus biomarker assessment and targeted therapies.
Increased activity in perivascular fibroblasts could precede motor-neuron degeneration and be a predictor of shorter survival in amyotrophic lateral sclerosis.
Results from the latest phase 3 clinical trial testing combinations of immunotherapy and tyrosine-kinase inhibitors for advanced kidney cancer improve standard first-line treatment options for patients.
A large genomic surveillance effort in South Africa produced 1,365 high-quality whole genomes of SARS-CoV-2; this has identified 16 new lineages of the virus that had not been identified in other countries.
Antisense oligonucleotides that target lamin A/C pre-mRNA decrease both progerin transcript levels and progerin protein levels and extend lifespan in an animal model of Hutchinson–Gilford progeria syndrome.
An analysis of life expectancy and cause of death in 363 Latin American cities unveils wide differences between cities in the same country, and sheds light on the socioeconomic factors that determine how long people live and how they die.